| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The compound's targets are not fully defined but are associated with pathways involved in promoting blood circulation, improving myocardial ischemia, and exerting weak inhibitory activity against H9C2 cardiomyocytes.
|
|---|---|
| ln Vitro |
In vitro, 20(R)-Notoginsenoside R2 exhibits weak inhibitory activity against H9C2 cells. It is also studied for its potential to protect cells from ischemic injury and modulate inflammatory responses.
|
| ln Vivo |
In vivo, this saponin promotes blood circulation and improves myocardial ischemia in animal models. It has been studied for therapeutic effects in cardiovascular diseases and may offer neuroprotection in models of neurodegeneration.
|
| Enzyme Assay |
Receptor binding assays are not well established for this compound. Studies typically use cell-based functional assays to assess its biological activity, such as measuring cell viability or markers of oxidative stress in cultured cells.
|
| Cell Assay |
H9C2 rat cardiomyoblast cells are cultured and treated with 20(R)-Notoginsenoside R2 at various concentrations. Cell viability is measured using MTT or CCK-8 assays to assess its cytotoxic or protective effects.
|
| Animal Protocol |
Myocardial ischemia models in rodents are used to evaluate cardioprotective effects. The compound is administered via oral gavage or intravenous injection, and parameters such as infarct size, ECG changes, and cardiac enzyme levels are measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies are limited. As a saponin, it likely has poor oral bioavailability due to high molecular weight and poor membrane permeability. It is typically administered parenterally in research settings.
|
| Toxicity/Toxicokinetics |
Specific toxicity data are limited. Saponins can cause hemolysis and gastrointestinal irritation at high doses. The compound is considered relatively safe at pharmacological doses based on its traditional use.
|
| References | |
| Additional Infomation |
20(R)-Notoginsenoside R2 is a research-grade natural product with no clinical trial or regulatory approval status. It is used primarily as a reference standard and in pharmacological studies of cardiovascular and neurodegenerative diseases.
|
| Molecular Formula |
C41H70O13
|
|---|---|
| Molecular Weight |
770.9867
|
| Exact Mass |
770.481
|
| CAS # |
948046-15-9
|
| PubChem CID |
16757287
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
878.7±65.0 °C at 760 mmHg
|
| Flash Point |
485.2±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| LogP |
6.45
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
54
|
| Complexity |
1360
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
C[C@@]12C[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@H]3C([C@H](CC[C@]3(C)[C@H]1C[C@@H](O)[C@@H]1[C@H](CC[C@@]21C)[C@@](O)(C)CC/C=C(\C)/C)O)(C)C
|
| InChi Key |
FNIRVWPHRMMRQI-RFMRREALSA-N
|
| InChi Code |
InChI=1S/C41H70O13/c1-20(2)10-9-13-41(8,50)21-11-15-39(6)28(21)22(43)16-26-38(5)14-12-27(45)37(3,4)34(38)24(17-40(26,39)7)52-36-33(31(48)30(47)25(18-42)53-36)54-35-32(49)29(46)23(44)19-51-35/h10,21-36,42-50H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26+,27-,28-,29-,30+,31-,32+,33+,34-,35-,36+,38+,39+,40+,41+/m0/s1
|
| Chemical Name |
(2S,3R,4S,5R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2970 mL | 6.4852 mL | 12.9703 mL | |
| 5 mM | 0.2594 mL | 1.2970 mL | 2.5941 mL | |
| 10 mM | 0.1297 mL | 0.6485 mL | 1.2970 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
